Kazuhiro Takehara

Prof. Dr. Kazuhiro Takehara

National Hospital Organization Shikoku Cancer Center
orcid

Research Focus & Metrics

Academic Career Length

18Years (2009-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
1 September 2016 in European Journal of Cancer
Verified
Journal Article
Closed access
TOTakashi Onda
Takashi Onda
TSToyomi Satoh
Toyomi Satoh
TSToshiaki Saito
Toshiaki Saito
TKTakahiro Kasamatsu
Takahiro Kasamatsu
TNToru Nakanishi
Toru Nakanishi
HYHiroyuki Yoshikawa
Hiroyuki Yoshikawa

20 November 2021 in Journal of Clinical Oncology
Verified
Journal Article
Open access
JHJunzo Hamanishi
Junzo Hamanishi
NTNobuhiro Takeshima
Nobuhiro Takeshima
NKNoriyuki Katsumata
Noriyuki Katsumata
KUKimio Ushijima
Kimio Ushijima
TKTadashi Kimura
Tadashi Kimura
IKIkuo Konishi
Ikuo Konishi
PURPOSE: This phase III, multicenter, randomized, open-label study investigated the efficacy and safety of nivolumab versus chemotherapy (gemcitabine [GEM] or pegylated liposomal doxorubicin [PLD]) in patients with platinum-resistant ovarian cancer. MATERIALS AND METHODS: Eligible patients had platinum-resistant epithelial ovarian cancer, received ≤ 1 regimen after diagnosis of resistance, and had an Eastern Cooperative Oncology Group performance score of ≤ 1. Patients were randomly assigned 1:1 to nivolumab (240 mg once every 2 weeks [as one cycle]) or chemotherapy (GEM 1000 mg/m2 for 30 minutes [once on days 1, 8, and 15] followed by a week's rest [as one cycle], or PLD 50 mg/m2 once every 4 weeks [as one cycle]). The primary outcome was overall survival (OS). Secondary outcomes included progression-free survival (PFS), overall response rate, duration of response, and safety. RESULTS: Patients (n = 316) were randomly assigned to nivolumab (n = 157) or GEM or PLD (n = 159) between October 2015 and December 2017. Median OS was 10.1 (95% CI, 8.3 to 14.1) and 12.1 (95% CI, 9.3 to 15.3) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.0; 95% CI, 0.8 to 1.3; P = .808). Median PFS was 2.0 (95% CI, 1.9 to 2.2) and 3.8 (95% CI, 3.6 to 4.2) months with nivolumab and GEM or PLD, respectively (hazard ratio, 1.5; 95% CI, 1.2 to 1.9; P = .002). There was no statistical difference in overall response rate between groups (7.6% v 13.2%; odds ratio, 0.6; 95% CI, 0.2 to 1.3; P = .191). Median duration of response was numerically longer with nivolumab than GEM or PLD (18.7 v 7.4 months). Fewer treatment-related adverse events were observed with nivolumab versus GEM or PLD (61.5% v 98.1%), with no additional or new safety risks. CONCLUSION: Although well-tolerated, nivolumab did not improve OS and showed worse PFS compared with GEM or PLD in patients with platinum-resistant ovarian cancer.

20 May 2023 in Journal of Clinical Oncology
Verified
Journal Article
Open access
TNTadaaki Nishikawa
Tadaaki Nishikawa
KHKosei Hasegawa
Kosei Hasegawa
KMKoji Matsumoto
Koji Matsumoto
MMMasahiko Mori
Masahiko Mori
YHYasuyuki Hirashima
Yasuyuki Hirashima
KYKan Yonemori
Kan Yonemori
PURPOSE: To investigate the efficacy and safety of trastuzumab deruxtecan, an antibody-drug conjugate targeting human epidermal growth factor receptor 2 (HER2) with a topoisomerase I inhibitor payload, in patients with uterine carcinosarcoma (UCS) expressing HER2. PATIENTS AND METHODS: Patients with recurrent UCS with HER2 immunohistochemistry scores ≥1+ previously treated with chemotherapy were included. Patients were assigned to the HER2-high (immunohistochemistry score ≥2+; n = 22) or low (immunohistochemistry score of 1+; n = 10) groups for primary and exploratory analyses, respectively. Trastuzumab deruxtecan 6.4 or 5.4 mg/kg was administered intravenously once every 3 weeks until unacceptable toxicity or disease progression. Dose modification was based on the updated recommended phase II dose for breast cancer to be 5.4 mg/kg. The primary end point was the objective response rate by central review in the HER2-high group. Secondary end points included the overall response rate (ORR) in the HER2-high group by investigator assessment, ORR in the HER2-low group, progression-free survival (PFS), overall survival (OS), and safety. RESULTS: The ORR by central review in the HER2-high and HER2-low groups were 54.5% (95% CI, 32.2 to 75.6) and 70.0% (95% CI, 34.8 to 93.3) and those by investigator assessments were 68.2% and 60.0%, respectively. The median PFS and OS in the HER2-high and HER2-low groups were 6.2 and 13.3 months and 6.7 months and not reached, respectively. Grade ≥ 3 adverse events occurred in 20 patients (61%). Grades 1-2 and 3 pneumonitis/interstitial lung disease occurred in eight (24%) and one (3%) patient, respectively. CONCLUSION: Trastuzumab deruxtecan has efficacy in patients with UCS, regardless of HER2 status. The safety profile was generally consistent with that previously reported. Toxicities were manageable with appropriate monitoring and treatment.

1 January 2024 in Journal of Gynecologic Oncology
Verified
Journal Article
Open access
PDF file
MSManabu Seino
Manabu Seino
SNSatoru Nagase
Satoru Nagase
HTHideki Tokunaga
Hideki Tokunaga
WYWataru Yamagami
Wataru Yamagami
YKYoichi Kobayashi
Yoichi Kobayashi
MMMikio Mikami
Mikio Mikami
Seino M, et al. J Gynecol Oncol. 2023 Nov;35(1):e15. https://doi.org/10.3802/jgo.2024.35.e15

15 June 2022 in Cancer Science
Verified
Journal Article
Open access
KYKan Yonemori
Kan Yonemori
YKYasutoshi Kuboki
Yasutoshi Kuboki
KHKosei Hasegawa
Kosei Hasegawa
TITakashi Iwata
Takashi Iwata
HKHidenori Kato
Hidenori Kato
KFKeiichi Fujiwara
Keiichi Fujiwara
New treatments, particularly second‐line options, are needed to improve outcomes for patients with recurrent/metastatic cervical cancer (r/mCC). Tisotumab vedotin (TV) is an antibody–drug conjugate directed to tissue factor, a transmembrane protein commonly expressed in cancer cells, to deliver cytotoxic monomethyl auristatin E. This single‐arm, open‐label phase 1/2 trial evaluated the consistency of safety and efficacy outcomes of TV in Japanese patients with r/mCC to bridge the current findings with those reported in previous trials in non‐Japanese patients in the United States and Europe. In part 1 (dose escalation; N = 6), patients with advanced solid tumors received TV 1.5 or 2.0 mg/kg once every 3 weeks to determine the maximum tolerated dose (MTD) and recommended phase 2 dose (RP2D). Part 2 (dose expansion; N = 17) evaluated the RP2D in r/mCC patients with 1–2 prior lines of therapy. In part 1, no dose‐limiting toxicities were observed, the MTD was not reached, and TV 2.0 mg/kg was established as the RP2D. In part 2, the most common treatment‐emergent adverse events were anemia (58.8%), nausea (58.8%), alopecia (47.1%), epistaxis (47.1%), and diarrhea (35.3%); adverse events of special interest were bleeding (76.5%), ocular events (35.3%), and peripheral neuropathy (17.6%), and were mostly grade 1/2. In part 2, confirmed objective response rate was 29.4%, median duration of response was 7.1 months, and median time to response was 1.2 months. In Japanese patients with r/mCC, TV demonstrated a manageable and tolerable safety, pharmacokinetics, and efficacy profile consistent with that observed in non‐Japanese patients.

6 May 2020 in Cancer Science
Verified
Journal Article
Open access
PDF file
MOMamiko Onuki
Mamiko Onuki
KMKoji Matsumoto
Koji Matsumoto
TITakashi Iwata
Takashi Iwata
KYKasumi Yamamoto
Kasumi Yamamoto
YAYoichi Aoki
Yoichi Aoki
FGfor MINT Study Group
for MINT Study Group
To obtain baseline data for cervical cancer prevention in Japan, we analyzed HPV data from 5045 Japanese women aged <40 years and diagnosed with cervical abnormalities at 21 hospitals during 2012‐2017. These included cervical intraepithelial neoplasia grade 1 (CIN1, n=573), CIN2‐3 (n=3219), adenocarcinoma in situ (AIS, n=123) and invasive cervical cancer (ICC, n=1130). The Roche Linear Array was used for HPV genotyping. HPV type‐specific relative contributions (RCs) were estimated by adding multiple infections to single types in accordance with proportional weighting attributions. Based on the comparison of type‐specific RCs between CIN1 and CIN2‐3/AIS/ICC (CIN2+), RC ratios were calculated to estimate type‐specific risks for progression to CIN2+. HPV DNA was detected in 85.5% of CIN1, 95.7% of CIN2‐3/AIS and 91.2% of ICC. Multiple infections decreased with disease severity: 42.9% in CIN1, 40.4% in CIN2‐3/AIS and 23.7% in ICC (P<0.0001). The relative risk for progression to CIN2+ was highest for HPV16 (RC ratio 3.78, 95% confidence interval [95%CI] 3.01‐4.98), followed by HPV31 (2.51, 1.54‐5.24), HPV18 (2.43, 1.59‐4.32), HPV35 (1.56, 0.43‐8.36), HPV33 (1.01, 0.49‐3.31), HPV52 (0.99, 0.76‐1.33) and HPV58 (0.97, 0.75‐1.32). The relative risk of disease progression was 1.87 (95%CI: 1.71‐2.05) for HPV16/18/31/33/35/45/52/58, but only 0.17 (95%CI: 0.14‐0.22) for HPV39/51/56/59/66/68. HPV16/18/31/33/45/52/58/6/11 included in a 9‐valent vaccine contributed to 89.7% (95%CI: 88.7‐90.7) of CIN2–3/AIS and 93.8% (95%CI: 92.4‐95.3) of ICC. In conclusion, our data support the Japanese guidelines that recommend discriminating HPV16/18/31/33/35/45/52/58 genotypes for CIN management. The 9‐valent vaccine is estimated to provide over 90% protection against ICC in young Japanese women.